Alejandro Diaz Chavez, MD
Pulmonary Disease · Roseburg, ORNPI 1851731004
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,569 of the $9,583 with a category attached, or 89.4%. Sanofi accounts for 90.8% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $8,703, more than ten times the $120 reported in 2019.
Across 48 payments — averaging $199.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$9K
- GSK$271
- AstraZeneca$184
- Genentech USA, Inc.$116
- Insmed, Inc.$93
- Sanofi-aventis U.S. LLC$89
- plus $127 from 5 others
What the payments were for
- Consulting fees$8,56989%
- Food & beverage$8098%
- Education$2052%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 2 | $8,703 |
| GSK | 21 | $271 |
| AstraZeneca | 10 | $184 |
| Genentech USA, Inc. | 2 | $116 |
| Insmed, Inc. | 5 | $93 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Boehringer Ingelheim | 2 | $43 |
| United Therapeutics Corporation | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Amgen | 1 | $20 |
| Mylan Specialty L.p. | 1 | $12 |
How this compares
$9,583 in reported general payments places this provider in the 85th percentile of 154 pulmonary disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 360 | $282,563 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $206,268 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 113 | $82,604 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 142 | $73,612 |
| Spiriva RespimatTiotropium Bromide | 111 | $61,117 |
| NucalaMepolizumab | 14 | $50,207 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 93 | $49,742 |
| Spiriva HandihalerTiotropium Bromide | 71 | $38,032 |
| Advair HfaFluticasone Propion/Salmeterol | 71 | $32,450 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 161 | $32,150 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 140 | $28,566 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $27,403 |
| Incruse ElliptaUmeclidinium Bromide | 64 | $21,321 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 34 | $20,000 |
| DuleraMometasone/Formoterol | 33 | $14,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Incruse Ellipta | $271 | $463,050679 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat, Striverdi Respimat | $43 | $133,990250 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $184 | $95,121153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 154 pulmonary disease providers in Oregon.
Other pulmonary disease in Roseburg
- Stephen YauPortland$984K
- Jeremy FeldmanBend$456K
- Matthew DrakePortland$135K
- Peter LeePortland$98K
- Matthew HegewaldBend$94K
- Jordan FeinPortland$87K
- Granthem FarrPortland$66K
- David HotchkinPortland$65K
- Jeffrey RobinsonPortland$51K
- John ButlerTualatin$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.